Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Summit Therapeutics Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 196
- +36 vs. Q3 2024
- Shares held
- 92.6M
- +8.24M (+9.8%) vs. Q3 2024
- Total value
- $1.65B
- −$193.8M (−10.5%) vs. Q3 2024
- New holders
- 62
- 75 more added
- Sold out
- 26
- 36 more reduced
4 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SMMT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 242 | $1.98B |
| Q1 2026 | 222 | $2.25B |
| Q4 2025 | 206 | $2.06B |
| Q3 2025 | 232 | $2.13B |
| Q2 2025 | 226 | $2.08B |
| Q1 2025 | 202 | $1.91B |
| Q4 2024 | 196 | $1.65B |
| Q3 2024 | 164 | $1.85B |
| Q2 2024 | 121 | $563.0M |
| Q1 2024 | 103 | $205.5M |
| Q4 2023 | 95 | $84.4M |
| Q3 2023 | 91 | $60.4M |
| Q2 2023 | 96 | $87.6M |
| Q1 2023 | 86 | $37.0M |
| Q4 2022 | 57 | $34.5M |
| Q3 2022 | 42 | $3.78M |
| Q2 2022 | 41 | $8.46M |
| Q1 2022 | 48 | $27.4M |
| Q4 2021 | 52 | $30.0M |
| Q3 2021 | 51 | $55.3M |
| Q2 2021 | 54 | $82.4M |
| Q1 2021 | 38 | $54.5M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Summit Therapeutics Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −168,094−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −128,894−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −56,024−100.0% | Sold out |
| Capital Fund Management S.A. | 0 | $0 | 0.00% | −29,764−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −23,915−100.0% | Sold out |
| Omers Administration Corp | 0 | $0 | 0.00% | −22,300−100.0% | Sold out |
| Nomura Holdings Inc | 0 | $0 | 0.00% | −18,967−100.0% | Sold out |
| Artia Global Partners LP | 0 | $0 | 0.00% | −14,512−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −13,963−100.0% | Sold out |
| Scientech Research LLC | 0 | $0 | 0.00% | −12,567−100.0% | Sold out |
| GTS Securities LLC | 0 | $0 | 0.00% | −12,432−100.0% | Sold out |
| Susquehanna Portfolio Strategies, LLC | 0 | $0 | 0.00% | −10,700−100.0% | Sold out |
| Acadian Asset Management LLC | 0 | $0 | 0.00% | −10,722−100.0% | Sold out |
| Alpine Global Management, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Fred Alger Management, LLC | 0 | $0 | 0.00% | −4,775−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −1,548−100.0% | Sold out |
| Darwin Advisors, LLC | 0 | $0 | 0.00% | −1,150−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −1,100−100.0% | Sold out |
| Global Retirement Partners, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Reuter James Wealth Management, LLC | 0 | $0 | 0.00% | −312−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −36−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −21−100.0% | Sold out |
| Ghost Tree Capital, LLC | – | – | – | – | Not filed |
| Inscription Capital, LLC | – | – | – | – | Not filed |
| PEAK6 Investments LLC | – | – | – | – | Not filed |
| Planning Capital Management Corp | – | – | – | – | Not filed |